7 analysts have expressed a variety of opinions on CME Gr CME over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 0 | 5 | 0 | 1 |
Last 30D | 0 | 0 | 0 | 0 | 1 |
1M Ago | 0 | 0 | 4 | 0 | 0 |
2M Ago | 1 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $221.0, a high estimate of $245.00, and a low estimate of $187.00. Observing a 0.91% increase, the current average has risen from the previous average price target of $219.00.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of CME Gr among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Andrew Bond | Rosenblatt | Raises | Sell | $187.00 | $185.00 |
Mike Cyprys | Morgan Stanley | Raises | Equal-Weight | $225.00 | $222.00 |
Benjamin Budish | Barclays | Raises | Equal-Weight | $226.00 | $225.00 |
Brian Bedell | Deutsche Bank | Lowers | Hold | $210.00 | $235.00 |
Kyle Voigt | Keefe, Bruyette & Woods | Maintains | Market Perform | $229.00 | - |
Kevin Heal | Argus Research | Raises | Buy | $245.00 | $225.00 |
Benjamin Budish | Barclays | Raises | Equal-Weight | $225.00 | $222.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CME Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CME Gr compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for CME Gr's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CME Gr's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on CME Gr analyst ratings.
About CME Gr
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The CME was founded in 1898 and in 2002 completed its initial public offering. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival, CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX in 2018, it has also expanded into cash foreign exchange, fixed income trading, and collateral optimization.
CME Gr: A Financial Overview
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: CME Gr's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 19.17%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 55.88%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CME Gr's ROE excels beyond industry benchmarks, reaching 2.93%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): CME Gr's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.63%, the company may face hurdles in achieving optimal financial returns.
Debt Management: CME Gr's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
How Are Analyst Ratings Determined?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.